Drug Discovery World

AUGUST 8, 2023

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.

Drugs 98

Drugs Protein Sales Production 98

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

The Pharma Data

JUNE 14, 2023

Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG. Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG.

Licensing 40

Licensing Licensing Life Science Development 40

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders.

Licensing 52

Licensing Licensing Drugs Development 52

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 40

Licensing Licensing Genome Genomics 40

pharmaphorum

JANUARY 11, 2023

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and immunology. before disease-related proteins are expressed). before disease-related proteins are expressed).

Protein 98

Protein Regulation FDA Approval Licensing 98

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. The companies have also commenced rolling submission for conditional marketing authorization from the European Medicines Agency (EMA) for this Omicron BA.4/BA.5-adapted

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. Gilead Sciences, Inc. View the full release here: [link]. About Dragonfly. Dragonfly Therapeutics, Inc.

Development 52

Development Research Licensing Licensing 52

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth. of Perspective’s shares for up to $33 million.

Drugs 59

Drugs Licensing Licensing Protein 59

pharmaphorum

JANUARY 21, 2021

This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research charities, convened and managed by the Medicines Discovery Catapult, that supports high-value drug discovery projects in this area of unmet patient need.

Medicine 111

Medicine Protein Drugs Research 111

XTalks

APRIL 3, 2024

Approximately ten to 20 percent of patients with PNH may develop extravascular hemolysis (EVH), a condition that causes RBC destruction outside of blood vessels. The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. While Soliris had its market launch 17 years ago with $3.2

FDA Approval 102

FDA Approval Sales Trials Development 102

The Pharma Data

AUGUST 3, 2021

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology. Transaction Terms.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

The Pharma Data

APRIL 12, 2023

Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ). We are pleased with Biogen’s decision to license ATV: Aβ and we are hopeful this will foster the development of next-generation anti- Aβ therapeutics.”

Antibody 40

Antibody Development Engineer Licensing 40

The Pharma Data

NOVEMBER 29, 2020

It has high expression in tumors and plays a key role in the occurrence and development of tumors. Binding to the MDM2 protein with high affinity, MDM2 inhibitor blocks the MDM2-p53 interactions and restore the tumor-suppressing activity of p53. We look forward to the further development of the asset by Ascentage Pharma.”

Licensing 40

Licensing Licensing Protein Drugs 40

The Pharma Data

AUGUST 17, 2020

. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. About Bristol Myers Squibb.

Licensing 52

Licensing Licensing Development Production 52

XTalks

FEBRUARY 19, 2024

In a recent study published by Weill Cornell Medicine in the Journal of Infectious Diseases , researchers have reported the potential of Moderna’s experimental mRNA vaccine in protecting adults against CMV, which could potentially also stop the transmission of the virus from mothers to their infants during pregnancy.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

DECEMBER 2, 2021

GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicines. Most notable is GSK’s $700 million upfront deal in the summer to license two drugs for neurological disease developed by US biotech Alector.

Biobanking 76

Biobanking Genome Genomics Genetics 76

The Pharma Data

DECEMBER 13, 2020

Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036. . CAMBRIDGE, Mass., 14, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. global head of pharma partnering, Roche.

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

pharmaphorum

FEBRUARY 4, 2022

” Nuvaxovid was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) yesterday, becoming the fifth COVID-19 vaccine to be authorised in the UK. It was also filed in the US earlier this month after development and manufacturing setbacks.

Vaccination 97

Vaccination Vaccine Protein Manufacturing 97

Drug Discovery World

AUGUST 9, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T cell therapy.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Licensing 52

Drug Discovery World

AUGUST 8, 2023

The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time $25 million payment for first refusal to license allogeneic CAR-T cell therapy P-MUC1C-ALLO1.

Gene Therapy 52

Gene Therapy Licensing Licensing Genetics 52

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. An estimated 1.57 The post Astellas teams up with UK biotech Mogrify on hearing loss project appeared first on.

In-Vivo 102

In-Vivo Bioinformatics Genetics Licensing 102

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

XTalks

DECEMBER 20, 2021

It has also applied for regulatory licensing in the UK, European Union (EU), Australia, Singapore, India, United Arab Emirates (UAE), New Zealand and Japan. Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Gavi secured 1.1

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

Pharmaceutical Technology

FEBRUARY 14, 2023

Alkaloids, natural dyes, drugs, proteins, and enzymes are some of the important classes of natural heterocyclic compounds essential for human life. The most common heteroatoms are nitrogen (N), oxygen (O) and sulphur (S). Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

Drug Discovery World

APRIL 5, 2023

It targets a pathway that cancer cells are highly dependent upon, involving the heat shock factor 1 protein (HSF1). Mechanism of action HSF1 is a transcription factor, meaning that it controls the production of other important proteins in the cell, through its regulation of the process of reading the genetic code stored in DNA.

Drugs 52

Drugs Scientist Clinical Trials Clinical Trials 52

pharmaphorum

DECEMBER 21, 2021

The front-loaded deal also includes $225 million in future payments tied to meeting development milestones, and adds to Sanofi’s current pipeline of around 20 oncology drug candidates. The Kadmon deal also included an immuno-oncology candidate – anti-PD-L1/IL-15 fusion protein KD033 – which is in early clinical development.

Licensing 122

Licensing Licensing Protein Clinical Development 122

The Pharma Data

NOVEMBER 30, 2020

The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”

Licensing 40

Licensing Licensing Production Development 40

pharmaphorum

DECEMBER 22, 2020

GlaxoSmithKline has closed the year with a flurry of deals, leaving its development pipeline bulging like Santa’s sack as chief scientific officer Hal Barron pursues a strategy to develop “transformational medicines”. million on the table if certain development, regulatory and sales goals are achieved.

Licensing 52

Licensing Licensing Genetics Sales 52

The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Protein Bioavailability DNA 52

pharmaphorum

OCTOBER 3, 2022

DMD is a severe, progressive muscle-wasting genetic condition caused by the lack of a protein called dystrophin. Translarna was the first licensed treatment for DMD which addresses the loss of dystrophin. Eventually, they will need assistance with breathing. The post Translarna not approved by NICE for DMD on NHS appeared first on.

Gene Therapy 91

Gene Therapy Gene FDA Approval DNA 91

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 61

Antibody Licensing Licensing Protein 61

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. Furthermore, atezolizumab is in Phase II clinical development by F.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

XTalks

JANUARY 29, 2021

They are both checkpoint inhibitors targeted towards programmed cell death protein 1 (PD-1 inhibitors), a protein that is responsible for downregulating the immune system and preventing it from killing cancer cells. Biosimilars are increasingly becoming the standard of care and both have several licensed biosimilar drugs (e.g.

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

Pharmaceutical Technology

NOVEMBER 9, 2022

CSL Behring has a commercialisation and license agreement to develop EtranaDez. Haemophilia A is caused by insufficient levels of the clotting protein factor VIII, while patients with haemophilia B lack adequate factor IX levels. BioMarin’s Roctavian has a target PDUFA action date of March 31 next year.

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278